Naegis Pharmaceuticals Inc.
Discovering new and safer ways to treat serious inflammatory diseases that impact hundreds of millions of patients worldwide.
Applying the most recent understanding of targets in arachidonic acid signaling pathways to discover and develop novel therapeutics for serious inflammatory diseases for which current treatment options are limited by lack of efficacy or poor side effect profile.
Focused on two proprietary programs:
PALI (peptidase augmentor, leukotriene inhibitor) - oral therapy for Chronic Obstructive Pulmonary Disease (COPD), a serious lung disease with high mortality affecting over 200 million globally, and prevalence increasing by 10% over the next decade
LTSI (leukotriene synthesis inhibitor) - topical therapy for uveitis, a condition that is responsible for some 10% of the legal blindness in the US and for which there are limited therapeutic options
Advancing towards near-term, high-value milestones.
Led by an experienced management team with demonstrated success and a Board of Directors composed of industry leaders.